Sema4, an AI- and machine learning-driven patient-centered genomic and clinical data intelligence company, and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, CM Life Sciences will be renamed and its common stock will be listed on the Nasdaq global market under a name and a ticker symbol to be announced at a later date.
Read the full article: Sema4, a Disruptive AI-Driven Genomic & Clinical Data Platform Company, to Combine with CM Life Sciences to Accelerate Growth //
Source: https://www.businesswire.com/news/home/20210210005493/en/%C2%A0Sema4-a-Disruptive-AI-driven-Genomic-Clinical-Data-Platform-Company-to-Combine-with-CM-Life-Sciences-to-Accelerate-Growth